Search Results - "ISHIKURA, Satoshi"

Prospective Trial of Stereotactic Body Radiation Therapy for Both Operable and Inoperable T1N0M0 Non-Small Cell Lung Cancer: Japan Clinical Oncology Group Study JCOG0403 by Nagata, Yasushi, MD, Hiraoka, Masahiro, MD, Shibata, Taro, MSc, Onishi, Hiroshi, MD, Kokubo, Masaki, MD, Karasawa, Katsuyuki, MD, Shioyama, Yoshiyuki, MD, Onimaru, Rikiya, MD, Kozuka, Takuyo, MD, Kunieda, Etsuo, MD, Saito, Tsutomu, MD, Nakagawa, Keiichi, MD, Hareyama, Masato, MD, Takai, Yoshihiro, MD, Hayakawa, Kazushige, MD, Mitsuhashi, Norio, MD, Ishikura, Satoshi, MD

“…Purpose To evaluate, in Japan Clinical Oncology Group study 0403, the safety and efficacy of stereotactic body radiation therapy (SBRT) in patients with T1N0M0…”
Get full text

Randomized study of low‐dose versus standard‐dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303) by Shinoda, Masayuki, Ando, Nobutoshi, Kato, Ken, Ishikura, Satoshi, Kato, Hoichi, Tsubosa, Yasuhiro, Minashi, Keiko, Okabe, Hiroshi, Kimura, Yusuke, Kawano, Tatsuyuki, Kosugi, Shin‐Ichi, Toh, Yasushi, Nakamura, Kenichi, Fukuda, Haruhiko

“…Low‐dose cisplatin and 5‐fluorouracil (LDPF) chemotherapy with daily radiotherapy (RT) is used as an alternative chemoradiotherapy regimen for locally advanced…”
Get full text

Multicenter prospective study of stereotactic body radiotherapy for previously untreated solitary primary hepatocellular carcinoma: The STRSPH study by Kimura, Tomoki, Takeda, Atsuya, Sanuki, Naoko, Ariyoshi, Keisuke, Yamaguchi, Takuhiro, Imagumbai, Toshiyuki, Katoh, Norio, Eriguchi, Takahisa, Oku, Yohei, Ozawa, Shuichi, Tsurugai, Yuichiro, Kokubo, Masaki, Shimizu, Shinichi, Ishikura, Satoshi

“…Aim To prospectively evaluate the efficacy and safety of stereotactic body radiotherapy (SBRT) for patients with previously untreated solitary primary…”
Get full text

Phase II Study of Chemoradiotherapy With 5-Fluorouracil and Cisplatin for Stage II–III Esophageal Squamous Cell Carcinoma: JCOG Trial (JCOG 9906) by Kato, Ken, M.D, Muro, Kei, M.D, Minashi, Keiko, M.D, Ohtsu, Atsushi, M.D, Ishikura, Satoshi, M.D, Boku, Narikazu, M.D, Takiuchi, Hiroya, M.D, Komatsu, Yoshito, M.D, Miyata, Yoshinori, M.D, Fukuda, Haruhiko, M.D

“…Purpose In this Phase II study, we evaluated the efficacy and toxicity of chemoradiotherapy (CRT) with cisplatin (CDDP) and 5-fluorouracil (5-FU) for Stage…”
Get full text

Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301) by Atagi, Shinji, Dr, Kawahara, Masaaki, MD, Yokoyama, Akira, MD, Okamoto, Hiroaki, MD, Yamamoto, Nobuyuki, MD, Ohe, Yuichiro, MD, Sawa, Toshiyuki, MD, Ishikura, Satoshi, MD, Shibata, Taro, MSc, Fukuda, Haruhiko, MD, Saijo, Nagahiro, MD, Tamura, Tomohide, MD

“…Summary Background It is unknown whether combined chemoradiotherapy improves overall survival in elderly patients with locally advanced non-small-cell lung…”
Get full text

Organ at risk delineation for radiation therapy clinical trials: Global Harmonization Group consensus guidelines by Mir, Romaana, Kelly, Sarah M., Xiao, Ying, Moore, Alisha, Clark, Catharine H., Clementel, Enrico, Corning, Coreen, Ebert, Martin, Hoskin, Peter, Hurkmans, Coen W., Ishikura, Satoshi, Kristensen, Ingrid, Kry, Stephen F., Lehmann, Joerg, Michalski, Jeff M., Monti, Angelo F., Nakamura, Mitsuhiro, Thompson, Kenton, Yang, Huiqi, Zubizarreta, Eduardo, Andratschke, Nicolaus, Miles, Elizabeth

“…•The GHG identified an unmet need for standardized OAR contouring guidance.•AAPM TG 263 recommendations exist for all but 10 OAR structures.•Here we present…”
Get full text

Phase I/II Study of Concurrent Chemoradiotherapy for Localized Nasal Natural Killer/T-Cell Lymphoma: Japan Clinical Oncology Group Study JCOG0211 by YAMAGUCHI, Motoko, TOBINAI, Kensei, WASADA, Izumi, KINOSHITA, Tomohiro, OHSHIMA, Koichi, MATSUNO, Yoshihiro, TERAUCHI, Takashi, NAWANO, Shigeru, ISHIKURA, Satoshi, KAGAMI, Yoshikazu, HOTTA, Tomomitsu, OSHIMI, Kazuo, OGUCHI, Masahiko, ISHIZUKA, Naoki, KOBAYASHI, Yukio, ISOBE, Yasushi, ISHIZAWA, Kenichi, MASEKI, Nobuo, ITOH, Kuniaki, USUI, Noriko

“…To explore a more effective treatment for localized nasal natural killer (NK)/T-cell lymphoma, we conducted a phase I/II study of concurrent chemoradiotherapy…”
Get full text

A randomized Phase III trial of comparing two dose-fractionations stereotactic body radiotherapy (SBRT) for medically inoperable Stage IA non-small cell lung cancer or small lung lesions clinically diagnosed as primary lung cancer: Japan Clinical Oncology Group Study JCOG1408 (J-SBRT trial) by Kimura, Tomoki, Nagata, Yasushi, Eba, Junko, Ozawa, Shuichi, Ishikura, Satoshi, Shibata, Taro, Ito, Yoshinori, Hiraoka, Masahiro, Nishimura, Yasumasa

“…A randomized Phase III trial commenced in Japan in February 2016. Currently, 42 Gy in four fractions of stereotactic body radiotherapy prescribed at the D of…”
Get full text

Study protocol for JCOG1807C (DEEP OCEAN): a interventional prospective trial to evaluate the efficacy and safety of durvalumab before and after operation or durvalumab as maintenance therapy after chemoradiotherapy against superior sulcus non-small cell lung cancer by Aokage, Keiju, Tsuboi, Masahiro, Zenke, Yoshitaka, Horinouchi, Hidehito, Nakamura, Naoki, Ishikura, Satoshi, Nishikawa, Hiroyoshi, Kumagai, Shogo, Koyama, Shohei, Kanato, Keisuke, Kataoka, Tomoko, Wakabayashi, Masashi, Fukutani, Miki, Fukuda, Haruhiko, Ohe, Yuichiro, Watanabe, Shun-ichi

“…Abstract Background Superior sulcus tumours (SSTs) are relatively uncommon and one of the most intractable lung cancers among non-small cell lung cancer…”
Get full text

Effects of replacing outdoor lighting with white LEDs with different correlated color temperatures on the attraction of nocturnal insects by Kamei, Mikio, Jikumaru, Shota, Hoshino, Shigeru, Ishikura, Satoshi, Wada, Masayuki

“…Currently, many sources of outdoor lighting are being replaced with light-emitting diodes (LEDs). Although conventional light sources that emit light in the…”
Get full text

Global Harmonization of Quality Assurance Naming Conventions in Radiation Therapy Clinical Trials by Melidis, Christos, MSc, Bosch, Walther R., DSc, Izewska, Joanna, PhD, Fidarova, Elena, MD, Zubizarreta, Eduardo, MD, Ulin, Kenneth, PhD, Ishikura, Satoshi, MD, Followill, David, Medical Physicist (Prof), Galvin, James, Medical Physicist (PhD), Haworth, Annette, Medical Physicist (Prof), Besuijen, Deidre, MSc, Clark, Clark H., PhD, Miles, Elizabeth, MSc, Aird, Edwin, PhD, Weber, Damien C, Hurkmans, Coen W., PhD, Verellen, Dirk, Medical Physicist (Prof)

“…Purpose To review the various radiation therapy quality assurance (RTQA) procedures used by the Global Clinical Trials RTQA Harmonization Group (GHG) steering…”
Get full text

A phase II study of adaptive two-step intensity-modulated radiation therapy (IMRT) with chemotherapy for loco-regionally advanced nasopharyngeal cancer (JCOG1015) by Nishimura, Yasumasa, Ishikura, Satoshi, Shibata, Taro, Kodaira, Takeshi, Ito, Yoshinori, Tsuchiya, Kazuhiko, Murakami, Yuji, Saitoh, Jun-ichi, Akimoto, Tetsuo, Nakata, Kensei, Yoshimura, Michio, Teshima, Teruki, Toshiyasu, Takashi, Ota, Yosuke, Ishikawa, Kazuki, Shimizu, Hidetoshi, Minemura, Toshiyuki, Nakamura, Kenichi, Hiraoka, Masahiro

“…Background A phase II study of adaptive two-step intensity-modulated radiotherapy (IMRT) with chemotherapy for nasopharyngeal cancer (NPC) (JCOG1015) was…”
Get full text

Stereotactic body radiotherapy using a radiobiology‐based regimen for stage I nonsmall cell lung cancer by Shibamoto, Yuta, Hashizume, Chisa, Baba, Fumiya, Ayakawa, Shiho, Manabe, Yoshihiko, Nagai, Aiko, Miyakawa, Akifumi, Murai, Taro, Iwata, Hiromitsu, Mori, Yoshimasa, Mimura, Mikio, Ishikura, Satoshi

“…BACKGROUND: The most common regimen of stereotactic body radiotherapy (SBRT) for stage I nonsmall cell lung cancer in Japan is 48 grays (Gy) in 4 fractions…”
Get full text

Optimal radiotherapy for non-small-cell lung cancer: current progress and future challenges by Ishikura, Satoshi

“…Radiotherapy has a key role in treating lung cancer. Advances in physics and computer technology have improved radiation delivery systems. With innovations in…”
Get full text

Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study by Kubota, Kaoru, Prof, Hida, Toyoaki, MD, Ishikura, Satoshi, MD, Mizusawa, Junki, MSc, Nishio, Makoto, MD, Kawahara, Masaaki, MD, Yokoyama, Akira, MD, Imamura, Fumio, MD, Takeda, Koji, MD, Negoro, Shunichi, MD, Harada, Masao, MD, Okamoto, Hiroaki, MD, Yamamoto, Nobuyuki, MD, Shinkai, Tetsu, MD, Sakai, Hiroshi, MD, Matsui, Kaoru, MD, Nakagawa, Kazuhiko, Prof, Shibata, Taro, MSc, Saijo, Nagahiro, Prof, Tamura, Tomohide, MD

“…Summary Background Four cycles of etoposide plus cisplatin and accelerated hyperfractionated thoracic radiotherapy (AHTRT) is the standard of care for…”
Get full text

Nimotuzumab combined with concurrent chemoradiotherapy in Japanese patients with esophageal cancer: A phase I study by Kato, Ken, Ura, Takashi, Koizumi, Wasaburo, Iwasa, Satoru, Katada, Chikatoshi, Azuma, Mizutomo, Ishikura, Satoshi, Nakao, Yoshinori, Onuma, Hiroshi, Muro, Kei

“…Nimotuzumab is a humanized anti‐epidermal growth factor receptor IgG1 monoclonal antibody. This phase I study assessed the tolerability, safety, efficacy, and…”
Get full text

Local radiotherapy for pleural dissemination of thymic tumors after initial treatment by Okazaki, Dai, Shibamoto, Yuta, Yanagi, Takeshi, Ishikura, Satoshi, Kondo, Takuhito, Yamada, Yuki, Niwa, Masanari

“…Abstract Pleural dissemination is a common pattern of failure after initial treatment of thymoma and thymic carcinoma, but there is no standardized treatment…”
Get full text

Toxicities of organs at risk in the mediastinal and hilar regions following stereotactic body radiotherapy for centrally located lung tumors by Nishimura, Shuichi, Takeda, Atsuya, Sanuki, Naoko, Ishikura, Satoshi, Oku, Yohei, Aoki, Yousuke, Kunieda, Etsuo, Shigematsu, Naoyuki

“…We investigated tolerable doses to organs at risk (OARs) in the mediastinum and pulmonary hilum following stereotactic body radiotherapy for centrally located…”
Get more information

Definitive chemoradiotherapy for squamous cell carcinoma of the esophagus: outcomes for borderline-resectable disease by Ishikura, Satoshi, Kondo, Takuhito, Murai, Taro, Ozawa, Yoshiyuki, Yanagi, Takeshi, Sugie, Chikao, Miyakawa, Akifumi, Shibamoto, Yuta

“…Abstract Definitive chemoradiotherapy (dCRT) is the standard treatment for unresectable esophageal cancer. Induction chemotherapy has been actively…”
Get full text

Final report of survival and late toxicities in the Phase I study of stereotactic body radiation therapy for peripheral T2N0M0 non-small cell lung cancer (JCOG0702) by Onimaru, Rikiya, Onishi, Hiroshi, Ogawa, Gakuto, Hiraoka, Masahiro, Ishikura, Satoshi, Karasawa, Katsuyuki, Matsuo, Yukinori, Kokubo, Masaki, Shioyama, Yoshiyuki, Matsushita, Haruo, Ito, Yoshinori, Shirato, Hiroki

“…A dose escalation study to determine the recommended dose with stereotactic body radiation therapy (SBRT) for peripheral T2N0M0 non-small cell carcinomas…”
Get full text